Business Context and Reporting Period
This Form 6-K filing, dated February 22, 2002, presents the Annual Report for Novartis AG for the fiscal year ended December 31, 2001. The report details the company's performance following the spin-off of its Agribusiness sector (now Syngenta) in late 2000. The company operates through five continuing sectors: Pharmaceuticals, Generics, Consumer Health, CIBA Vision, and Animal Health. The reporting period reflects a strategic focus on healthcare, particularly the Pharmaceuticals business and the US market.
Key Financial Metrics
| Metric | 2001 (CHF millions) | 2000 (CHF millions) | Change |
|---|---|---|---|
| Sales (Continuing Activities) | 32,038 | 29,112 | +10% (CHF) / +14% (Local Currencies) |
| Operating Income | 7,277 | 6,727 | +8% |
| Net Income (Continuing Activities) | 7,024 | 6,511 | +8% |
| Free Cash Flow | 4,073 | 3,254 | +25% (Excl. Roche stake & acquisitions) |
| Operating Margin | 22.7% | 23.1% | -0.4 pp |
| Return on Average Equity | 17.8% | 19.5% | -1.7 pp |
| Debt/Equity Ratio | 0.18:1 | 0.16:1 | Increased |
| Current Ratio | 2.4:1 | 2.8:1 | Decreased |
| Earnings Per Share (Continuing) | CHF 2.73 | CHF 2.49 | +10% |
| Dividend Per Share (Proposed) | CHF 0.90 | CHF 0.85 | +6% |
Material Changes vs. Prior Period
- Sales Growth: Group sales grew 10% in Swiss francs, driven primarily by the Pharmaceuticals sector (+11% CHF, +15% local currencies). The US market accounted for 43% of total Group sales, up from 40% in 2000.
- Pharmaceuticals Performance: Sales reached CHF 20.2 billion. Key growth drivers included Diovan (hypertension), which became the top-selling product, and Glivec/Gleevec (chronic myeloid leukemia), which generated CHF 257 million in less than 8 months post-launch.
- Generics Expansion: Sales increased 23% in CHF due to strategic acquisitions in the USA, Europe, and Argentina, and the launch of generic Prozac.
- CIBA Vision: Sales rose 28% in CHF, largely due to the full-year impact of the Wesley Jessen acquisition and strong performance of the Focus contact lens range.
- Animal Health Decline: Sales fell 11% in CHF due to inventory reductions at US veterinary clinics and the foot-and-mouth disease crisis in Europe.
- Strategic Investment: Novartis acquired a 21.3% voting stake in Roche Holding AG for approximately CHF 5.2 billion, accounted for using the equity method.
- Shareholder Returns: The company completed a second share buy-back program totaling CHF 3.9 billion and proposed a dividend increase to CHF 0.90 per share.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management expects Pharmaceutical sales to increase in the "high single-digit to low double-digit range" in 2002. The operating margin is expected to be maintained at the previous year's level, barring unforeseen changes. Key launches anticipated for 2002 include Elidel (eczema) in the USA and Europe, Foradil for COPD, and Glivec/Gleevec in Japan and major European countries.
Risks and Contingencies
- Regulatory and Pricing Pressure: The company faces increasing pressure from government actions, price reductions, reference pricing, and parallel imports, particularly in the EU and USA.
- Patent Expirations: Loss of patent protection for key products (e.g., Sandimmun/Neoral, Voltaren) continues to impact sales, though the rate of decline is described as modest.
- Environmental Liabilities: Novartis maintains a provision of CHF 228 million for environmental remediation costs related to past operations. Management believes reserves are adequate but notes inherent uncertainties in estimating future costs.
- Legal Proceedings: The company is a defendant in various actions, including antitrust and pricing violations alleged by US retail pharmacies. Management believes these actions are without merit.
- Market Risk: Significant exposure to foreign exchange fluctuations (USD, EUR, JPY) and interest rate changes, managed through derivative instruments.
Investor Verification Checklist
- Roche Investment Impact: Verify the accounting treatment and future income statement impact of the 21.3% stake in Roche Holding AG, including goodwill amortization and equity method adjustments.
- Pharmaceutical Pipeline: Confirm the regulatory status and commercial potential of key pipeline products, specifically COX189 (pain/arthritis) and Xolair (asthma), which faced FDA data requests.
- Generics Integration: Assess the integration progress and profitability of recent Generics acquisitions (Apothecon, BASF, Labinca, Lagap) and their contribution to margin stability.
- Patent Cliff Management: Monitor sales trends of mature products like Sandimmun/Neoral and Voltaren to ensure generic erosion remains within forecasted limits.
- Environmental Provisions: Review the adequacy of the CHF 228 million environmental provision against potential future remediation costs at legacy sites.
- Share Buy-back Completion: Confirm the finalization of the CHF 4 billion share repurchase program and its impact on outstanding share count and EPS.